|
View this as a webpage
Influenza vaccine prebook for the 2025-2026 season opened on Jan. 16. Prebook requests are due Jan. 31. Requests submitted after Jan. 31 will be considered late. Late requests cannot be guaranteed and may arrive later in the season. Providers enrolled in the Minnesota Vaccine for Children (MnVFC) program will use the Minnesota Immunization Information Connection (MIIC) to prebook. If you have not yet submitted your flu prebook request, follow the instructions below on how to prebook influenza vaccine.
- Login to Minnesota Immunization Information Connection.
- Go to the vaccine management header on the left-hand side.
- Select request special event vaccine.
- From the event dropdown, select 2025-2026 MnVFC pediatric influenza vaccine prebook.
The Advisory Committee on Immunization Practices (ACIP) recommends administering the Respiratory Syncytial Virus (RSV) vaccine, Abrysvo to pregnant people at 32 to 36 weeks gestation from September through January. This strategy provides maternal antibodies to infants who are born when RSV activity is high.
- Administering maternal RSV vaccine starting in September (at least 1 month before the start of the RSV season) and continuing through January (at least 2 months before the end of the season) maximizes cost-effectiveness and benefits of the vaccine.
- Administering vaccine after January may not be covered by the pregnant person’s insurance.
- Infants born before April 1 to unvaccinated pregnant person should be offered nirsevimab, the RSV monoclonal antibody.
For additional information, visit:
The package insert for Moderna’s RSV vaccine mResvia was revised in December 2024 with new instructions for thawing frozen vaccine. Syringes may be kept at room temperature for up to 24 hours and stored in the refrigerator for up to 90 days. See Table 1 of the following document for details, Moderna: mResvia Package Insert (PDF).
On Jan. 7, the Food and Drug Administration (FDA) shared information about a labeling change to the prescribing information for Abrysvo (Pfizer) and Arexvy (GSK) RSV vaccines. Labels for both RSV vaccines will now state that the results of a post-marketing observational study suggest an increased risk of Guillain-Barre Syndrome (GBS) during the 42 days following vaccination. For detailed information, visit FDA: FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy.
Evidence suggesting an increased risk of GBS with Abrysvo and Arexvy have been reviewed by the FDA and ACIP, but the available evidence is insufficient to establish a causal relationship. The current Vaccine Information Statement (VIS) for RSV Vaccine (PDF) states that GBS has been reported after RSV vaccination in some older adults and that increased risk of GBS following RSV vaccine among persons 60 years and older cannot be confirmed or ruled out. If ACIP recommendations change, the VIS will be updated.
Did you know that measles, mumps and rubella (MMR) vaccine can be given as early as 6 months of age to infants who are traveling internationally? When assessing immunization needs at a child’s 6 month well child visit, ask the family if they have plans to travel in the next 6 months. Give MMR at the 6 months visit along with all other recommended vaccinations if the child will be traveling internationally before their first birthday. This early MMR dose will not count toward the child’s routine MMR immunizations so be sure to give another dose after the child turns 12 months old. Travel was linked to several Minnesota cases during the 2024 measles outbreak. Measles is only a plane ride away!
|
